PAS
CSTL icon

Point72 Asia (Singapore)’s Castle Biosciences CSTL Stock Holding History

Point72 Asia (Singapore)’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-253
Closed -$5.5K – 1046
2024
Q2 		$5.5K Buy
+253
New +$5.64K ﹤0.01% 961

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asia (Singapore)'s CSTL Position: Q3 2024 in Review

Point72 Asia (Singapore) sold out of Castle Biosciences (CSTL) in Q3 2024, closing a stake of 253 shares — an estimated $5.5K sold.

Point72 Asia (Singapore) first reported a position in CSTL in Q2 2024 and held it in 1 quarter. The position peaked at $5.5K in Q2 2024. 185 funds tracked by Wall St. Rank hold CSTL as of Q3 2024.

  • Point72 Asia (Singapore) reported no remaining Castle Biosciences position as of Q3 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 253 Castle Biosciences shares in Q3 2024, an estimated $5.5K.
  • Point72 Asia (Singapore) first reported a position in Castle Biosciences in Q2 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Castle Biosciences position peaked at $5.5K in Q2 2024.
  • 185 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2024, filed 14 Nov 2024.